Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma - Trial NCT06302699
Access comprehensive clinical trial information for NCT06302699 through Pure Global AI's free database. This phase not specified trial is sponsored by Institute of Hematology & Blood Diseases Hospital, China and is currently Recruiting. The study focuses on Multiple Myeloma. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Institute of Hematology & Blood Diseases Hospital, China
Timeline & Enrollment
N/A
May 01, 2023
Mar 01, 2026
Primary Outcome
Detection of copy number variation
Summary
The presence of minimal residual disease (MRD) is an important prognostic factor for multiple
 myeloma, while copy number variation (CNV) is a widely accepted biomarker used for multiple
 myeloma (MM). Detecting MRD and monitoring clonal evolution by monitoring CNV using low-pass
 whole genome sequencing is promising due to its high analytical sensitivity. To evaluate the
 correlation between MRD detected by flow cytometry and low-pass whole genome sequencing,
 nearly 200 samples were collected for this study. We applied ultrasensitive chromosomal
 aberrations detection to detect CNV for each patient. The follow-up samples were then
 collected and sequencing used the same method.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06302699
Non-Device Trial